238 research outputs found
sj-docx-3-chi-10.1177_17423953211060253 - Supplemental material for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT
No full textSupplemental material, sj-docx-3-chi-10.1177_17423953211060253 for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness</p
sj-docx-2-chi-10.1177_17423953211060253 - Supplemental material for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT
No full textSupplemental material, sj-docx-2-chi-10.1177_17423953211060253 for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness</p
sj-docx-1-chi-10.1177_17423953211060253 - Supplemental material for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT
No full textSupplemental material, sj-docx-1-chi-10.1177_17423953211060253 for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness</p
BPBF Podcast Episode 2: Being a Mentor and Educator
No full textDr. Corrie Claiborne talks with Dr. Daniel Black about mentorship, education, writing, and hosting Spiritual Time video broadcasts.
Resources: Dr. Black's biography can be found here: https://us.macmillan.com/author/danielblack/ AUC Woodruff Library Digital Repository (RADAR) provides hosting for historical materials in the AUC: https://radar.auctr.edu/ Africana Digital Ethnography Project (ADEPt) provides music for this podcast: https://africanadept.org
BPBF Podcast Episode 1: 1526
No full textIn this first episode, Dr. Corrie Claiborne interviews Dr. Samuel Livingston (Morehouse Africana Studies) about his research, including the 1526 Project and Gullah Geechee history and culture.
Resources: Dr. Livingston's biography (https://www.morehouse.edu/faculty-profiles-home/first-and-last-name-23702-en.html); "Mapping the Low Country" article (https://auctr.on.worldcat.org/oclc/8419433639); Julius S. Scott, "The Common Wind" (https://auctr.on.worldcat.org/oclc/1053198144); "Legacy of Igbo Landing" (https://auctr.on.worldcat.org/oclc/39723608); AUC Woodruff Library Digital Repository, RADAR (https://radar.auctr.edu/); Africana Digital Ethnography Project, ADEPt (https://africanadept.org/
BPBF Podcast Episode 3: How Do You Educate People for Liberation?
No full textDr. Corrie Claiborne talks with Dr. Richard Benson about the education of Black people and Critical Race Theory.
Dr. Benson's profile: https://www.spelman.edu/academics/faculty/directory/profile/richard-benson
Dr. Benson's book, Fighting for Our Place in the Sun: https://www.peterlang.com/view/title/22031?tab=aboutautho
Abstract CT066: Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma
No full textAbstract
Background: Poor outcome in pancreatic ductal adenocarcinoma (PDA) is associated partly with stromal hyaluronan (HA) accumulation, which may compromise chemotherapy access to tumors. In animal models, PEGPH20 degrades HA in tumors. Key endpoint data from a phase 2 study showed that PEGPH20 plus chemotherapy improved efficacy over chemotherapy alone in tumors retrospectively identified to accumulate HA (“HA-High”). The objectives of this phase 3 study are to compare efficacy and safety of standard-dose nab-paclitaxel (NAB) and gemcitabine (GEM) combined with either PEGPH20 or placebo in patients with HA-High, previously untreated, Stage IV PDA. Primary endpoints are progression-free survival (PFS) and overall survival (OS). Secondary endpoints are objective response rate, duration of response, and safety.
Methods: 420 patients ≥18 years with untreated HA-High metastatic PDA, ECOG PS 0-1 will be randomized (stratified by geographic region: North America/Europe/Other) 2:1 to NAB 125 mg/m2 + GEM 1000 mg/m2 + PEGPH20 3.0 μg/kg or to placebo. Patients with HA-High tumors will be prospectively identified by the co-developed VENTANA HA RxDx Assay, which indicates HA in the extracellular matrix. HA-High status (indicating patients who may achieve clinical benefit) was determined by Halozyme to be ≥50% staining based on clinical outcome data from a phase 2 study. Treatment will be provided in 4 week cycles (Wk 13, Wk 4 rest) until disease progression, unacceptable toxicity, death, or consent withdrawal. PEGPH20 or placebo will be given twice weekly (Cycle 1) then weekly (Cycles 2+), NAB + GEM once weekly for all cycles. Dexamethasone will be given before and after PEGPH20 administrations to reduce treatment related musculoskeletal symptoms and enoxaparin will be given to minimize thromboembolic events. Tumor response will be assessed by an independent central imaging vendor using RECIST v1.1. Adverse events will be graded per NCI CTCAE v4.03. An independent Data Monitoring Committee will evaluate safety and data for PFS and OS. Trial initiated Q12016 (EudraCT 2015-004068-13; NCT02715804).
Citation Format: Lei Zheng, Andrew E. Hendifar, Michele Reni, William P. Harris, Michel Ducreux, Andrea J. Bullock, Pippa G. Corrie, Tara Seery, Dimitrios Chondros, Eric Van Cutsem. Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT066. doi:10.1158/1538-7445.AM2017-CT066</jats:p
- …
